"Ki-1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. It is found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of the Ki-1 antigen in hematopoietic malignancies make it clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Descriptor ID |
D017730
|
MeSH Number(s) |
D12.776.543.750.705.852.760.072 D23.050.285.025 D23.101.140.055
|
Concept/Terms |
Ki-1 Antigen- Ki-1 Antigen
- Antigen, Ki-1
- Ki 1 Antigen
- CD30 Antigens
- Antigens, CD30
- Ber-H2 Antigen
- Antigen, Ber-H2
- Ber H2 Antigen
- TNFRSF8 Receptor
- Receptor, TNFRSF8
- Antigens, Ki-1
- Antigens, Ki 1
- Ki-1 Antigens
- Ki 1 Antigens
- Tumor Necrosis Factor Receptor Superfamily, Member 8
- CD30 Antigen
- Antigen, CD30
- Ber-H2 Antigens
- Antigens, Ber-H2
- Ber H2 Antigens
|
Below are MeSH descriptors whose meaning is more general than "Ki-1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "Ki-1 Antigen".
This graph shows the total number of publications written about "Ki-1 Antigen" by people in this website by year, and whether "Ki-1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 3 | 1 | 4 |
1999 | 0 | 1 | 1 |
2000 | 0 | 1 | 1 |
2001 | 1 | 1 | 2 |
2002 | 0 | 1 | 1 |
2003 | 1 | 0 | 1 |
2004 | 0 | 1 | 1 |
2005 | 1 | 1 | 2 |
2006 | 1 | 1 | 2 |
2007 | 2 | 1 | 3 |
2009 | 1 | 1 | 2 |
2010 | 0 | 2 | 2 |
2011 | 2 | 2 | 4 |
2012 | 1 | 3 | 4 |
2013 | 5 | 0 | 5 |
2014 | 8 | 2 | 10 |
2015 | 4 | 2 | 6 |
2016 | 2 | 4 | 6 |
2017 | 2 | 0 | 2 |
2018 | 1 | 0 | 1 |
2019 | 1 | 2 | 3 |
2020 | 2 | 0 | 2 |
2021 | 2 | 1 | 3 |
2022 | 0 | 3 | 3 |
2023 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ki-1 Antigen" by people in Profiles.
-
Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas. Hematol Oncol Clin North Am. 2023 Dec; 37(6):1107-1124.
-
CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology. 2023 Jul; 83(1):143-148.
-
Lymphomatoid papulosis with DUSP22-IRF4 rearrangement: A case report and literature review. J Cutan Pathol. 2023 Aug; 50(8):711-716.
-
Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022 10 11; 6(19):5550-5555.
-
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma. Oncologist. 2022 Oct 01; 27(10):864-873.
-
The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity. Sci Rep. 2022 06 21; 12(1):10488.
-
Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma. Cancer Rep (Hoboken). 2022 07; 5(7):e1581.
-
Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clin Cancer Res. 2021 07 01; 27(13):3744-3756.
-
Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. Eur J Cancer. 2021 05; 148:411-421.
-
Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders? Virchows Arch. 2021 Aug; 479(2):377-383.